Gilead Sciences, Inc. (GILD)

Market Cap	148.53B
Revenue (ttm)	29.09B
Net Income (ttm)	8.11B
Shares Out	1.24B
EPS (ttm)	6.42
PE Ratio	18.58
Forward PE	14.06
Dividend	$3.16 (2.65%)
Ex-Dividend Date	Dec 15, 2025

Volume	492,168
Open	118.61
Previous Close	118.15
Day's Range	118.58 - 119.77
52-Week Range	86.08 - 124.61
Beta	0.33
Analysts	Buy
Price Target	120.90 (+0.99%)
Earnings Date	Oct 30, 2025

About GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Jan 22, 1992
• Employees: 17,600
• Stock Exchange: NASDAQ
• Ticker Symbol: GILD
• Website: https://www.gilead.com

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Analyst Summary

According to 22 analysts, the average rating for GILD stock is "Buy." The 12-month stock price target is $120.9, which is an increase of 0.99% from the latest price.

Price Target

$120.9

(0.99% upside)

Analyst Consensus: Buy